27,684 findings
- Energy balanceStrong
Participants at the intervention sites lost significantly more weight (−8.0±6.7 kg) compared to control sites (+0.6±2.8 kg, p<0.0001).
Worksite interventions can effectively promote weight loss among employees.
Supports Sourced - Energy balanceStrong
The intervention led to significant improvements in systolic blood pressure (−8.6±12.6 mmHg) compared to control (+5.5±10.8 mmHg, p<0.0001).
Worksite interventions can lead to better blood pressure management.
Supports Sourced - HormonalStrong
Retatrutide administered at a 12 mg dosage resulted in significant reductions in body weight, body mass index, and waist circumference.
Practitioners can consider retatrutide as an effective treatment option for obesity.
Supports Sourced - HormonalStrong
A higher percentage of patients receiving retatrutide achieved weight losses of ≥5%, 10%, 15%, and 20% compared to placebo.
Retatrutide may be particularly effective for patients aiming for significant weight loss.
Supports Sourced - Energy balanceStrong
Efsubaglutide Alfa produced a mean weight reduction of 7.16% versus 0.86% with placebo.
Efsubaglutide Alfa may be an effective treatment option for weight loss in individuals with obesity or overweight.
Supports Sourced - Energy balanceStrong
82.5% of Efsubaglutide-treated participants achieved ≥5% weight loss.
A significant proportion of individuals treated with Efsubaglutide Alfa can expect to achieve clinically meaningful weight loss.
Supports Sourced - Energy balanceStrong
Cagrisema produced significantly greater percentage weight loss than semaglutide with a mean difference of -7.47% (95% CI: -10.58, -4.36; p < 0.001).
Cagrisema may be a more effective option for weight loss in obese patients compared to semaglutide.
Supports Sourced - Energy balanceStrong
Cagrilintide monotherapy weight loss was comparable to semaglutide.
Cagrilintide may be a viable alternative to semaglutide for weight management in obese patients.
Supports Sourced - Energy balanceStrong
Cagrisema is safe and has a comparable side effect profile to semaglutide.
Cagrisema can be considered a safe option for weight management in obese patients.
Supports Sourced - Energy balanceStrong
Meal replacements (MRs) led to a greater reduction in body weight by -1.38 kg compared to conventional food-based weight loss diets.
Incorporating meal replacements can be an effective strategy for weight loss in individuals at risk of metabolic syndrome.
Supports Sourced - Energy balanceStrong
MRs resulted in a reduction in body mass index (BMI) by -0.56 kg/m2 compared to conventional diets.
Using meal replacements can help reduce BMI in at-risk populations.
Supports Sourced - Metabolic adaptationStrong
Incorporating MRs into a weight loss intervention leads to reductions in LDL-c by -0.18 mmol/L and non-HDL-c by -0.17 mmol/L.
Meal replacements can improve lipid profiles in individuals at risk of metabolic syndrome.
Supports Sourced - HormonalStrong
Retatrutide treatment for 48 weeks resulted in a least-squares mean percentage change in body weight of -24.2% in the 12 mg group compared to -2.1% in the placebo group.
Retatrutide may be an effective treatment option for significant weight loss in adults with obesity.
Supports Sourced - HormonalStrong
A weight reduction of 5% or more occurred in 100% of participants who received 8 mg of retatrutide.
The 8 mg dose of retatrutide is highly effective for achieving at least a 5% weight loss in this population.
Supports Sourced - Metabolic adaptationStrong
Various types of physical activity enhance health and glycemic management in people with type 2 diabetes.
Practitioners should encourage a variety of physical activities to improve health and glycemic control in patients with type 2 diabetes.
Supports Sourced - Metabolic adaptationStrong
People with type 2 diabetes should engage in physical activity regularly and reduce sedentary time.
Encourage patients to incorporate regular physical activity and minimize sedentary behavior.
Supports Sourced - Metabolic adaptationStrong
Exercise timing may maximize glucose-lowering effects.
Consider advising patients on the timing of exercise to enhance glucose management.
Supports Sourced - Metabolic adaptationStrong
Various types of physical activity enhance health and glycemic management in people with type 2 diabetes.
Practitioners should encourage a variety of physical activities to improve health and glycemic control in patients with type 2 diabetes.
Supports Sourced - Metabolic adaptationStrong
People with type 2 diabetes should engage in physical activity regularly and reduce sedentary time.
Encourage patients to incorporate regular physical activity and minimize sedentary behavior.
Supports Sourced - Metabolic adaptationStrong
Exercise timing may maximize glucose-lowering effects.
Consider advising patients on the timing of exercise to enhance glucose management.
Supports Sourced - HormonalStrong
A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group compared to 22.4% in the placebo group.
Semaglutide may help reduce liver fibrosis in patients with MASH.
Supports Sourced - Energy balanceStrong
The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo.
Semaglutide may lead to significant weight loss in patients with MASH.
Supports Sourced - Energy balanceStrong
Participation in high-intensity programs for 6 months can lead to weight loss of up to 8 kg (8% of weight) and improvements in cardiovascular disease risk factors and quality of life.
Clinicians should recommend high-intensity lifestyle modification programs for effective weight loss.
Supports Sourced - Energy balanceStrong
To prevent weight regain, participation in weight-loss-maintenance programs for 1 year with at least monthly counseling is recommended.
Clinicians should implement long-term maintenance strategies to support weight loss sustainability.
Supports Sourced